Clinuvel Pharmaceuticals (UR9) Price & Analysis
UR9 Stock Chart & Stats
- Day’s Range
- EUR 4.43 - EUR 4.43
- 52-Week Range
- EUR 4.35 - EUR 7.45
- Previous Close
- EUR 4.57
- Volume
- 0
- Average Volume (3M)
- 123
- Market Cap
- EUR 228.65M
- Enterprise Value
- EUR 272.15M
- Total Cash (Recent Filing)
- EUR 252.06M
- Total Debt (Recent Filing)
- EUR 1.94M
- Price to Earnings (P/E)
- 10.6
- Beta
- 0.54
- Next Earnings
- Feb 23, 2027
- EPS Estimate
- 0.16
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 0.69%
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet
Near-zero leverage materially reduces financial risk and interest burden, preserving flexibility to fund research, commercialization, or other priorities internally. The steady increase in equity also provides a durable capital base, helping the company withstand weaker operating periods without relying heavily on debt.
Strong Cash Conversion
Operating cash flow exceeding net income indicates that reported earnings are converting into cash effectively, supporting business self-funding and financial resilience. Consistently positive free cash flow gives Clinuvel capacity to sustain operations and invest in development while limiting dependence on external capital.
Established Profitability
Sustained high gross and net margins demonstrate that the commercial business has historically generated meaningful profit from its revenue base. This profitability can support continued commercialization and research investment, while providing a stronger foundation than an early-stage company dependent on future funding.
Bears Say
Revenue Contraction And Margin Reset
The return to negative revenue growth interrupts the prior expansion trend and raises concern about the durability of commercial momentum. A sharp gross-margin reduction may also weaken operating leverage, making future earnings more sensitive to product mix, pricing, or cost changes even though net margin remains healthy.
Slowing Free Cash Flow Growth
Positive free cash flow remains a strength, but its 2026 contraction signals that cash-generation momentum has weakened alongside the softer operating trajectory. If sustained, slower cash growth could reduce the pace at which Clinuvel funds research, commercialization, or shareholder returns from internal resources.
Declining Return On Equity
Falling return on equity indicates that the company is generating less profit relative to its accumulated equity base than it did previously. This may reflect moderating profitability or a faster-growing capital base, and it reduces the efficiency of shareholder capital deployment even with minimal balance-sheet leverage.
Clinuvel Pharmaceuticals News
UR9 FAQ
What was Clinuvel Pharmaceuticals ’s price range in the past 12 months?
What is Clinuvel Pharmaceuticals ’s market cap?
When is Clinuvel Pharmaceuticals ’s upcoming earnings report date?
How were Clinuvel Pharmaceuticals ’s earnings last quarter?
Is Clinuvel Pharmaceuticals overvalued?
Does Clinuvel Pharmaceuticals pay dividends?
What is Clinuvel Pharmaceuticals ’s EPS estimate?
How many shares outstanding does Clinuvel Pharmaceuticals have?
What happened to Clinuvel Pharmaceuticals ’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Clinuvel Pharmaceuticals ?
What is the TipRanks Smart Score and how is it calculated?
Clinuvel Pharmaceuticals Stock Smart Score
Company Description
Clinuvel Pharmaceuticals
Clinuvel Pharmaceuticals Limited is a biopharmaceutical company focused on the development and commercialization of treatments for patients battling genetic, metabolic, and life-threatening conditions. Its reach extends across Australia, Europe, the United States, Switzerland, and other global markets. The company's flagship drug, SCENESSE, serves as a systemic photoprotective treatment intended to prevent phototoxicity in adult patients diagnosed with erythropoietic protoporphyria (EPP). Clinuvel's development pipeline includes CUV9900, an alpha-melanocyte stimulating hormone analogue; Parvysmelanotide (VLRX001), which promotes prolonged cellular activity; and PRÉNUMBRA, a liquid injectable formulation of afamelanotide. Additionally, Clinuvel Pharmaceuticals has partnered with HK Winhealth Pharma Group Co. Limited for a named patient program in the People's Republic of China, enabling the treatment of EPP patients with SCENESSE. Founded in 1987, the company's corporate headquarters are situated in Melbourne, Australia.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Philippe Jacques Wolgen
- Employees
- 16
- Website
- www.clinuvel.com
- Address
- 535 Bourke Street, Melbourne, VIC, 3000, AU
Clinuvel Pharmaceuticals (UR9) Earnings & Revenues
UR9 Company Deck
UR9 Earnings Call
Earnings Call SentimentPositive
The call conveys a generally positive outlook driven by modest revenue growth, record first-half sales, strong cash reserves and sustained profitability while management deliberately invests in in-house R&D, clinical and manufacturing capabilities. Those positives are tempered by materially higher operating expenses across personnel, R&D and corporate areas, a non-cash FX translation loss, and timing/uncertainty around regulatory filings (CUV107 completion required before submission) and the NASDAQ ADR uplift. On balance, the company emphasizes that expense increases are strategic investments supported by a strong balance sheet and cash runway.
View all DE:UR9 earnings summariesUR9 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 2 | 5 | 15 |
| Technical Analysis | 2 | 5 | 3 |
| Moving Averages | 0 | 0 | 12 |